The funds will fuel LifeCell's Growth Plan Across Divisions and
Foray into Adjacent Categories
Chennai, September 22, 2021:
LifeCell International Private Limited, India’s leading stem cell bank and reproductive genetic testing services provider, today announces the successful fundraise of ₹225cr from OrbiMed Asia Partners IV, a leading healthcare investment firm. As part of this round the existing founders of LifeCell shall also participate by investing ₹30cr.
Commenting on the fund raise, Mayur Abhaya, Managing Director, LifeCell International, noted "We thank OrbiMed for backing LifeCell to support its growth. Having transformed the approach in cord blood stem cell preservation through its innovative community banking model, LifeCell has over the last few years undertaken several growth initiatives in genetic and genomic testing for maternal and newborn health, and innovative placental tissue-based products for wound healing. With demonstrated market leadership across segments, LifeCell seeks to further leverage its technological expertise, strong brand position, and wide network, to foray into adjacent new categories like Fertility Heath and Cell-based therapeutics. These funds will help accelerate this agenda and further strengthen our market position".
Dr. Sunny Sharma, Senior Managing Director, OrbiMed Asia, will join the Board of LifeCell upon closure of this transaction. Dr. Sharma said, “LifeCell has built a trusted healthcare brand in maternal and newborn health through innovation and service. We are very excited to partner with Mayur and his team in the next stage of LifeCell’s growth”.
Ernst & Young LLP acted as the investment banking advisor to LifeCell and LKS acted as the legal advisor.
About LifeCell International Private Limited
Established in 2004 at Chennai, LifeCell is India’s leading provider of human cell, genes and tissue based products and services for preventive and therapeutic purposes. It operates the country’s largest registry of newborn stem cells with >60,000 qualifying cord blood units readily available for release to its member network when needed in transplants. LifeCell also runs a national network of advanced genetic testing laboratories catering to 3,000+ hospitals across 130 cities, with primary focus on maternal and newborn health. Further, the recently setup transplants division at LifeCell offers innovative placental and umbilical cord derived stem cell and tissue based products for applications in advanced wound care and immunomodulation.
OrbiMed is a leading healthcare investment firm with over $19 billion in assets under management. OrbiMed invests globally across the healthcare industry through a range of private equity funds, public equity funds, and royalty/credit funds.
OrbiMed’s team of over 100 professionals is based in New York City, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya and other key global markets.